News Snapshot:
October 21, 2020 FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo TOKYO (Reuters) – Japan’s Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza. Carelink will use Fujifilm’s data on Avigan’s treatment of novel coronavirus infections and influenza to seek imported drug approval in China, Fujifilm said in a statement. The...
